Edel A McNeela
Overview
Explore the profile of Edel A McNeela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vo T, McNeela E, ODonovan O, Rani S, Mehta J
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682150
Background: HER2-positive breast cancer is an aggressive subtype where innate/acquired resistance to targeted drugs remains a challenge. This study aims to uncover the underlying mechanisms of HER2 drug resistance through...
2.
Vo T, El-Sherbieny Abdelaal E, Jordan E, ODonovan O, McNeela E, Mehta J, et al.
Biochem Biophys Rep
. 2023 Dec;
37:101588.
PMID: 38088952
Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four...
3.
Davitt C, McNeela E, Longet S, Tobias J, Aversa V, McEntee C, et al.
J Control Release
. 2016 May;
233:162-73.
PMID: 27157995
Diarrhoeal infections are a major cause of morbidity and mortality with enterotoxigenic Escherichia coli (ETEC) and cholera imposing a significant global burden. There is currently no licensed vaccine for ETEC....
4.
Misstear K, McNeela E, Murphy A, Geoghegan J, OKeeffe K, Fox J, et al.
J Infect Dis
. 2013 Nov;
209(9):1479-84.
PMID: 24273045
Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not...
5.
Mori A, Oleszycka E, Sharp F, Coleman M, Ozasa Y, Singh M, et al.
Eur J Immunol
. 2012 Jul;
42(10):2709-19.
PMID: 22777876
Alum is the principal vaccine adjuvant for clinical applications but it is a poor inducer of cellular immunity and is not an optimal adjuvant for vaccines where Th1 responses are...
6.
McNeela E, Burke A, Neill D, Baxter C, Fernandes V, Ferreira D, et al.
PLoS Pathog
. 2010 Nov;
6(11):e1001191.
PMID: 21085613
Pneumolysin (PLY) is a key Streptococcus pneumoniae virulence factor and potential candidate for inclusion in pneumococcal subunit vaccines. Dendritic cells (DC) play a key role in the initiation and instruction...
7.
Luthi A, Cullen S, McNeela E, Duriez P, Afonina I, Sheridan C, et al.
Immunity
. 2009 Jun;
31(1):84-98.
PMID: 19559631
Interleukin-33 (IL-33) is a member of the IL-1 family and is involved in polarization of T cells toward a T helper 2 (Th2) cell phenotype. IL-33 is thought to be...
8.
Huo Z, Sinha R, McNeela E, Borrow R, Giemza R, Cosgrove C, et al.
Infect Immun
. 2005 Nov;
73(12):8256-65.
PMID: 16299322
Thirty-six healthy volunteers received either a single intramuscular injection of Neisseria meningitidis serogroup C polysaccharide (MCP)-CRM197 conjugate vaccine in alum or two nasal insufflations 28 days apart of the same...
9.
Bowe F, Lavelle E, McNeela E, Hale C, Clare S, Arico B, et al.
Infect Immun
. 2004 Jun;
72(7):4052-60.
PMID: 15213150
Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, which is still a major cause of meningitis. We evaluated the immunogenicity of...
10.
McNeela E, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, et al.
Vaccine
. 2004 May;
22(8):909-14.
PMID: 15161067
We previously reported that intranasal immunization with a non-toxic mutant cross-reacting material (CRM)197 of diphtheria toxin, formulated with chitosan, generated protective neutralizing antibodies in mice and guinea pigs. Furthermore, we...